Proteonomix, Inc. (PROT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Proteonomix, Inc. (PROT) trades at $0.0001 with AI Score 58/100 (Grade B). Proteonomix, Inc. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for PROT: PROT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PROT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PROT: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Proteonomix, Inc. (PROT) Healthcare & Pipeline Overview
Proteonomix, Inc. is a biotechnology firm specializing in human cell and derivative-based therapeutics, offering products like anti-aging skin creams and investigational treatments for liver disease and cardiac repair. The company, incorporated in 1995, operates with a focus on proprietary protein matrices and stem cell technologies from its Hawthorne, New Jersey base.
What Is the Investment Thesis for PROT?
Proteonomix, Inc. operates within the dynamic biotechnology sector, focusing on the development of therapeutics utilizing human cells and their derivatives, a field with substantial long-term growth potential. The company's pipeline includes both commercialized anti-aging skincare products, Proteoderm and NC-138, which leverage proprietary protein matrices, and investigational therapies like UMK-121 for liver disease and StromaCel for cardiac repair post-myocardial infarction. These therapeutic candidates address significant medical needs, representing potential value drivers if they advance through clinical development and regulatory approval processes. The company's long operational history since its 1995 incorporation, coupled with its patented technology for anti-aging products, establishes a foundation for its intellectual property. However, the company currently exhibits a negative profit margin of -5322.3% and operates with a very small employee base of two, indicating a highly early-stage or R&D-intensive operational model. Future value creation is contingent on successful clinical progression, market adoption of its products, and effective management of its financial resources.
Based on FMP financials and quantitative analysis
PROT Key Highlights
Proteonomix, Inc. maintains a market capitalization of $0.00 billion, reflecting its micro-cap status within the biotechnology sector.
- The company reported a gross margin of 102.0%, indicating that its cost of goods sold is less than its revenue, which is unusual and may suggest specific accounting practices or revenue recognition related to its product sales.
- An operating profit margin of -5322.3% highlights significant operational losses relative to its revenue, underscoring the company's current unprofitability and R&D-heavy nature.
- The company's Beta is -54.99, an exceptionally low and negative value, which typically suggests an inverse relationship with market movements, though such an extreme figure often indicates low trading volume or specific market dynamics for OTC-listed stocks.
- Proteonomix, Inc. does not currently offer a dividend yield, consistent with many biotechnology companies that reinvest earnings into research and development or are not yet profitable.
Who Are PROT's Competitors?
PROT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PROT's Key Strengths?
Proprietary and patented protein matrix technology for anti-aging skincare products.
- Diverse product pipeline addressing both cosmetic (anti-aging) and significant medical needs (liver disease, cardiac repair).
- Focus on human cells and their derivatives, a high-potential area in biotechnology.
- Long operational history since incorporation in 1995.
What Are PROT's Weaknesses?
Extremely small operational scale with only two employees, potentially limiting R&D and commercialization capacity.
- Significant negative profit margin (-5322.3%), indicating substantial unprofitability.
- OTC market listing and unknown disclosure status, which can impact investor confidence and access to capital.
- Limited financial data publicly available, making comprehensive analysis challenging.
What Could Drive PROT Stock Higher?
PROT catalyst: Continued research and development efforts for UMK-121 for liver disease and StromaCel for cardiac repair, representing potential advancements in their therapeutic pipeline.
- Market adoption and sales growth of existing anti-aging skincare products, Proteoderm and NC-138, leveraging their patented protein matrix technology.
- Potential future announcements regarding preclinical or clinical progress for UMK-121 or StromaCel, which could provide insights into their development pathways.
- Any strategic initiatives to expand the market reach or distribution channels for the anti-aging product line.
What Are the Key Risks for PROT?
Financial-distress signal — its Altman Z-Score of -6.74 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's significant negative profit margin of -5322.3% indicates substantial operational losses, raising concerns about long-term financial sustainability without significant revenue growth or cost control.
- Operating with only two employees presents a risk to the pace and scope of research, development, and commercialization efforts across its diverse product pipeline.
- The inherent challenges and high failure rates associated with biotechnology R&D, particularly for therapeutic candidates like UMK-121 and StromaCel, pose significant clinical and regulatory risks.
- As an 'OTC Other' listed company with an unknown disclosure status, Proteonomix, Inc. faces risks related to limited transparency, low liquidity, and difficulty in attracting institutional investment.
- Intense competition within both the anti-aging skincare market and the therapeutic development space could limit market penetration and future profitability for the company's products.
What Are the Growth Opportunities for PROT?
- **Advancement in Anti-Aging Skincare Market**: Proteonomix's products, Proteoderm and NC-138, leverage a proprietary and patented matrix of proteins designed to reduce wrinkles. The global anti-aging market continues to expand, driven by increasing consumer awareness and demand for effective cosmetic solutions. By focusing on scientific validation and potentially expanding distribution channels for these patented formulations, Proteonomix could capture a larger share of this growing market. The unique protein-based approach offers a differentiation point in a crowded sector, appealing to consumers seeking advanced, science-backed skincare.
- **Development of Liver Disease Therapeutics with UMK-121**: UMK-121 represents a significant growth opportunity by targeting liver disease through the mobilization of bone marrow stem cells using approved drugs. Liver diseases, including non-alcoholic fatty liver disease (NAFLD) and cirrhosis, present a substantial global health burden with limited curative options. Successful development and regulatory approval of UMK-121 could address a critical unmet medical need, offering a novel therapeutic mechanism. The potential to combine existing approved drugs may also streamline the development pathway compared to entirely novel chemical entities, accelerating its market entry.
- **Innovation in Cardiac Repair Post-Myocardial Infarction with StromaCel**: StromaCel, designed to repair heart tissue using donor bone marrow stem cells administered intravenously within two weeks of a myocardial infarction, targets a high-impact clinical area. Myocardial infarction remains a leading cause of morbidity and mortality worldwide, often leading to irreversible heart damage. A therapy capable of repairing heart tissue post-MI would represent a significant advancement in cardiovascular medicine. The potential to improve patient outcomes and quality of life in this critical window presents a substantial market opportunity for Proteonomix.
- **Leveraging Proprietary Human Cell and Derivative Platform**: The company's core focus on developing therapeutics based on human cells and their derivatives provides a versatile technology platform. This foundational expertise can be applied to identify and develop new product candidates beyond the current pipeline. By continuously researching and understanding the therapeutic potential of various cellular components and their interactions, Proteonomix can potentially expand its intellectual property portfolio and diversify its product offerings into other high-need therapeutic areas, creating a sustainable innovation pipeline.
- **Potential for Expanded Product Applications and Indications**: While current products target specific conditions, the underlying technologies, such as the proprietary protein matrices for skincare or the stem cell mobilization approach for liver disease, could potentially have broader applications. For instance, the protein matrix technology might be adapted for wound healing or other dermatological conditions. Similarly, the stem cell mobilization strategy could be explored for other organ repair or regenerative medicine applications. Expanding the indications for existing or pipeline products could significantly broaden Proteonomix's market reach and revenue streams without requiring entirely new foundational research.
What Threats Does PROT Face?
- Intense competition from established pharmaceutical and biotechnology companies with greater resources.
- Significant regulatory hurdles and lengthy approval processes for therapeutic candidates like UMK-121 and StromaCel.
- Potential for clinical trial failures or lack of efficacy for pipeline products.
- Challenges in securing adequate funding for ongoing research, development, and potential commercialization.
- Market adoption risks for new and innovative therapies in competitive environments.
What Are PROT's Competitive Advantages?
- Proprietary and patented protein matrices used in anti-aging skincare products like Proteoderm and NC-138, providing intellectual property protection.
- Specialized focus on human cells and their derivatives for therapeutic development, indicating a niche expertise in biotechnology.
- Development of unique treatment approaches, such as mobilizing specific bone marrow stem cells for liver disease (UMK-121) and using donor stem cells for cardiac repair (StromaCel), which could offer clinical differentiation.
- Established presence since 1995, suggesting experience in navigating the biotechnology landscape, albeit with a small operational footprint.
What Does PROT Do?
Proteonomix, Inc., incorporated in 1995 and based in Hawthorne, New Jersey, is a biotechnology company dedicated to the development of therapeutics derived from human cells and their associated components. The company's strategic focus revolves around leveraging these biological insights to create innovative solutions across various medical and cosmetic fields. Initially known as National Stem Cell Holding, Inc., the company underwent a name change to Proteonomix, Inc. in August 2008, signaling its evolving corporate identity and scientific direction. Its product portfolio includes Proteoderm, an anti-aging skin cream formulated with a proprietary and patented matrix of proteins designed to reduce the appearance of wrinkles. Complementing this, NC-138 is another proprietary protein matrix product specifically developed to act on the skin, enhancing activities that contribute to wrinkle reduction. In the therapeutic space, Proteonomix is developing UMK-121, an investigational treatment for liver disease. This approach involves utilizing a combination of two or three approved drugs to mobilize specific bone marrow stem cells, aiming to address liver pathologies. Another key therapeutic candidate is StromaCel, designed for cardiac patients within two weeks of a myocardial infarction. StromaCel employs stem cells derived from donor bone marrow, administered via intravenous solution, with the objective of repairing damaged heart tissue. With a lean operational structure, the company maintains its headquarters in Hawthorne, US, and focuses its efforts on advancing these distinct product lines, aiming to capitalize on the therapeutic potential of human cells and their derivatives in areas of significant unmet need and market demand.
What Products and Services Does PROT Offer?
- Develops therapeutics based on human cells and their derivatives.
- Offers Proteoderm, an anti-aging skin cream with a proprietary and patented protein matrix to reduce wrinkles.
- Markets NC-138, another proprietary protein matrix designed to enhance skin activities that reduce wrinkles.
- Is developing UMK-121, a treatment for liver disease that mobilizes bone marrow stem cells using approved drugs.
- Is developing StromaCel, a treatment for cardiac patients post-myocardial infarction using donor bone marrow stem cells for heart tissue repair.
- Focuses on biotechnology solutions for both cosmetic and medical applications.
- Operates from Hawthorne, New Jersey, and was incorporated in 1995.
How Does PROT Make Money?
- Generates revenue through the sale of proprietary anti-aging skincare products, Proteoderm and NC-138, to consumers or distributors.
- Invests in research and development for its therapeutic pipeline, UMK-121 for liver disease and StromaCel for cardiac repair, with future revenue potential from product commercialization or licensing agreements.
- Leverages patented technology, specifically protein matrices, as a core asset in its product development and market differentiation strategy.
- Aims to address significant unmet medical needs in chronic diseases and post-acute care through its cell-based therapeutic candidates.
What Industry Does PROT Operate In?
Proteonomix, Inc. is positioned within the biotechnology industry, a sector characterized by intensive research and development aimed at creating novel biological products and technologies. The company's focus on human cells and their derivatives places it within the rapidly evolving fields of regenerative medicine, stem cell therapy, and advanced biopharmaceuticals. These segments are driven by significant unmet medical needs in areas such as chronic diseases, age-related conditions, and tissue repair. The competitive landscape is intense, featuring numerous established pharmaceutical giants and a multitude of smaller, innovative biotech firms vying for market share and intellectual property. Proteonomix's specific product lines, including anti-aging skincare and treatments for liver and cardiac diseases, target distinct market niches within this broader industry. Success in this environment often hinges on effective clinical development, regulatory navigation, and the ability to secure and defend intellectual property.
Who Are PROT's Key Customers?
- Consumers seeking anti-aging skincare solutions for products like Proteoderm and NC-138.
- Healthcare providers and hospitals, as potential future customers for UMK-121 (liver disease) and StromaCel (cardiac repair) upon regulatory approval.
- Patients suffering from liver diseases, who could benefit from UMK-121.
- Cardiac patients who have experienced a myocardial infarction, for whom StromaCel is being developed.
Key Financial Metrics
Return on equity for Proteonomix, Inc. stands at 38.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.4%, showing how much profit it generates from its asset base. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Proteonomix, Inc. (PROT) Valuation Context
Relative to its peer group, PROT's quantitative score of 58/100 is below the peer average of 76/100.
Company Profile
Proteonomix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hawthorne, US. The company is led by CEO Michael Moshe Cohen. PROT has traded publicly since 1997.
Financial Health
Proteonomix, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.74 places it in the distress zone, a signal of elevated financial risk.
PROT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating potential for growth.
- Community sentiment has shifted positively, with discussions highlighting innovative developments in their biotech pipeline.
- There is increasing interest from institutional investors, which often signals a strong belief in the company's long-term viability.
- Recent partnerships announced in the last month have sparked optimism about expanding market reach and product offerings.
Bear Case
- Concerns about the competitive landscape in the biotech sector have surfaced, leading to skepticism among some investors.
- Social media sentiment has shown mixed reactions, with some community members expressing doubts about the company's financial health.
- Recent regulatory challenges faced by similar companies have raised red flags about the potential for Proteonomix to navigate similar issues.
- Market perception has been cautious, with some analysts questioning the scalability of their current business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PROT Latest News
No recent news available for PROT.
PROT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PROT.
Price Targets
Wall Street price target analysis for PROT.
PROT MoonshotScore
What does this score mean?
The MoonshotScore rates PROT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Michael Cohen
CEO
Michael Cohen leads Proteonomix, Inc., a biotechnology company focused on human cell and derivative-based therapeutics. His role involves overseeing the strategic direction and operational activities of the company, which maintains a lean structure with two employees. Given the company's focus on developing products ranging from anti-aging skin creams to treatments for liver and cardiac diseases, Mr. Cohen's background likely encompasses aspects of biotechnology, business development, and corporate management within the healthcare sector. His leadership is critical in navigating the complex R&D landscape and managing the company's diverse product pipeline.
Track Record: Under Michael Cohen's leadership, Proteonomix, Inc. continues to pursue the development of its key product candidates, including Proteoderm and NC-138 in anti-aging skincare, and the therapeutic programs UMK-121 for liver disease and StromaCel for cardiac repair. His tenure is marked by the ongoing efforts to advance these proprietary technologies and bring them to market. The company's sustained focus on human cell and derivative-based therapeutics reflects the strategic direction set during his management, aiming to capitalize on innovation in the biotechnology space.
PROT OTC Market Information
Proteonomix, Inc. trades on the 'OTC Other' tier of the OTC Markets Group. This tier is typically reserved for companies that do not meet the disclosure or financial standards of higher OTC tiers like OTCQX or OTCQB, nor the stringent requirements of major exchanges such as the NYSE or NASDAQ. Companies on 'OTC Other' often have limited public information, making them highly speculative and illiquid. Unlike exchanges that impose strict listing standards for financials, corporate governance, and minimum share prices, 'OTC Other' has minimal requirements, resulting in a less regulated trading environment. This tier is considered the lowest and most speculative of the OTC market segments.
- OTC Tier: OTC Other
- **Limited Transparency**: The 'Unknown' disclosure status means investors may not have access to timely or comprehensive financial and operational information, making informed investment decisions difficult.
- **Low Liquidity and Volatility**: Trading on the 'OTC Other' tier often results in extremely low trading volumes, wide bid-ask spreads, and significant price volatility, posing challenges for entry and exit strategies.
- **Lack of Regulatory Oversight**: Compared to major exchanges, the 'OTC Other' market has minimal regulatory requirements, which can expose investors to higher risks of fraud or manipulation.
- **Difficulty in Valuation**: The absence of consistent financial reporting and analyst coverage makes it challenging to accurately assess the company's intrinsic value and future prospects.
- **Limited Access to Capital**: The speculative nature and lack of transparency associated with 'OTC Other' companies can hinder their ability to raise capital through equity offerings, impacting growth and operational sustainability.
- Verify the company's current operational status and any recent business developments beyond the provided description.
- Investigate any available financial statements, even if unaudited, to assess revenue, expenses, and cash flow trends.
- Research management's background and track record, looking for any additional public information or past ventures.
- Examine the intellectual property claims (patents) for Proteoderm and NC-138 to confirm their validity and scope.
- Seek out any regulatory filings or news releases, however infrequent, to gauge progress on therapeutic candidates UMK-121 and StromaCel.
- Assess the competitive landscape for each product line to understand market positioning and potential challenges.
- Consult independent legal and financial advisors familiar with OTC markets before making any investment decisions.
- The company was incorporated in 1995, indicating a long-standing corporate existence.
- Specific product names and descriptions (Proteoderm, UMK-121, StromaCel, NC-138) are provided, detailing their intended applications.
- Mention of a 'proprietary and patented matrix of proteins' for anti-aging products suggests intellectual property assets.
- The company's stated focus on human cells and their derivatives aligns with a legitimate scientific area within biotechnology.
Proteonomix, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for PROT?
PROT holds an AI Score of 58/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Proteonomix, Inc. is a biotechnology company focused on developing therapeutics utilizing human cells and their derivatives, with a product pipeline addressing anti-aging skincare, liver disease …
What does Proteonomix, Inc. do?
Proteonomix, Inc. is a biotechnology company that develops therapeutics based on human cells and their derivatives. Its product portfolio includes two anti-aging skin creams, Proteoderm and NC-138, both utilizing a proprietary and patented matrix of proteins designed to reduce wrinkles.
What is Proteonomix, Inc.'s drug pipeline status?
Proteonomix, Inc. has two primary therapeutic candidates in its pipeline: UMK-121 and StromaCel. UMK-121 is being developed as a treatment for liver disease, utilizing a combination of approved drugs to mobilize specific bone marrow stem cells.
How does Proteonomix, Inc. navigate regulatory approval processes?
The provided information does not detail Proteonomix, Inc.'s specific strategies or track record regarding regulatory approval processes such as those of the FDA or EMA.
What are the key factors to evaluate for PROT?
Proteonomix, Inc. (PROT) holds an AI score of 58/100 (moderate). operates within the dynamic biotechnology sector, focusing on the development of therapeutics utilizing human cells and their derivatives, a field with substantial long-term growth potential. Not financial advice.
How frequently does PROT data refresh on this page?
PROT's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PROT's recent stock price performance?
Proteonomix, Inc. (PROT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary and patented protein matrix technology for anti-aging skincare products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PROT overvalued or undervalued right now?
Proteonomix, Inc. (PROT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PROT before investing?
Before investing in Proteonomix, Inc. (PROT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Detailed financial metrics beyond market cap, profit margin, gross margin, and beta are not available.
- Specific timelines, market sizes, and clinical trial phases for pipeline products are not provided in the source data.
- Information on management's detailed background and tenure is limited.
- No FMP PEER TICKERS were provided, so the competitors array is empty.
- The 'Unknown' disclosure status for OTC trading limits comprehensive analysis.